MX2019014597A - Inhibidores de pirazolopirimidina de pde9. - Google Patents

Inhibidores de pirazolopirimidina de pde9.

Info

Publication number
MX2019014597A
MX2019014597A MX2019014597A MX2019014597A MX2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A MX 2019014597 A MX2019014597 A MX 2019014597A
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidine
present
compounds
pde9
pde9 inhibitors
Prior art date
Application number
MX2019014597A
Other languages
English (en)
Inventor
Raghavan Subharekha
Arasappan Ashok
Tyagarajan Sriram
Li Derun
M Cox Jason
S Debenham John
Guo Zhuyan
He Jiafang
Hussain Zahid
Lai Zhong
Meng Dongfang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019014597A publication Critical patent/MX2019014597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de pirazolopirimidina que pueden ser útiles como agentes terapéuticos para el tratamiento de trastornos asociados con la fosfodiesterasa 9 (PDE9). La presente invención también se refiere al uso de dichos compuestos para tratar enfermedades cardiovasculares y cerebrovasculares, tales como hipertensión, enfermedad renal crónica e insuficiencia cardíaca, y trastornos neurológicos y psiquiátricos, tales como esquizofrenia, psicosis o enfermedad de Huntington, y los asociados con hipofunción estriatal o disfunción de los núcleos basales.
MX2019014597A 2017-06-08 2018-06-06 Inhibidores de pirazolopirimidina de pde9. MX2019014597A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516903P 2017-06-08 2017-06-08
US201862665840P 2018-05-02 2018-05-02
PCT/US2018/036172 WO2018226771A1 (en) 2017-06-08 2018-06-06 Pyrazolopyrimidine pde9 inhibitors

Publications (1)

Publication Number Publication Date
MX2019014597A true MX2019014597A (es) 2020-02-05

Family

ID=62779024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014597A MX2019014597A (es) 2017-06-08 2018-06-06 Inhibidores de pirazolopirimidina de pde9.

Country Status (13)

Country Link
US (2) US10934294B2 (es)
EP (1) EP3634964B1 (es)
JP (1) JP2020523309A (es)
KR (1) KR20200013758A (es)
CN (1) CN111051308A (es)
AU (1) AU2018281131B2 (es)
BR (1) BR112019025813A2 (es)
CA (1) CA3064938A1 (es)
MA (1) MA53841A (es)
MX (1) MX2019014597A (es)
RU (1) RU2019144010A (es)
TW (1) TW201902898A (es)
WO (1) WO2018226771A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018281131B2 (en) 2017-06-08 2022-01-20 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE9 inhibitors
EP3893881A4 (en) * 2018-12-12 2022-08-17 Merck Sharp & Dohme Corp. CYCLOBUTYLPYRAZOLOPYRIMIDINE PDE9 INHIBITORS
EP3894413B1 (en) * 2018-12-12 2023-11-15 Merck Sharp & Dohme LLC Pyrazolopyrimidine pde9 inhibitors
CN114773256B (zh) * 2022-03-23 2024-05-03 中国农业大学 一种4-氰基哌啶的合成方法
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的系统和方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE71183B1 (en) 1988-12-27 1997-01-29 Takeda Chemical Industries Ltd Guanidine derivatives their production and insecticides
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2004505054A (ja) 2000-08-01 2004-02-19 バイエル　アクチェンゲゼルシャフト 知覚を改善する医薬品としての選択的ｐｄｅ２インヒビター
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
ES2526701T3 (es) 2005-06-14 2015-01-14 Aska Pharmaceutical Co., Ltd. Derivado de tienopirimidina
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
ES2581573T3 (es) 2006-08-08 2016-09-06 Aska Pharmaceutical Co., Ltd. Derivado de quinazolina
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
RS52166B (en) 2007-05-11 2012-08-31 Pfizer Inc. AMINO-HETEROCYCLIC COMPOUNDS
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
MX2011010184A (es) 2009-03-31 2011-10-28 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4 -ona y su uso como moduladores de pde9a.
AR077859A1 (es) 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
CN105541849B (zh) * 2010-08-12 2018-03-23 勃林格殷格翰国际有限公司 6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途
DK2669270T3 (en) 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2906562B1 (en) 2011-10-10 2016-10-05 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
KR101706216B1 (ko) 2012-04-03 2017-02-13 한화테크윈 주식회사 고밀도 삼차원 영상 재구성 장치 및 방법
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017019726A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Oxy-cyanoquinolinone pde9 inhibitors
US10370336B2 (en) 2015-07-29 2019-08-06 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone PDE9 inhibitors
US10376504B2 (en) 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
AU2018281131B2 (en) * 2017-06-08 2022-01-20 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE9 inhibitors

Also Published As

Publication number Publication date
US11028092B2 (en) 2021-06-08
KR20200013758A (ko) 2020-02-07
MA53841A (fr) 2021-09-22
EP3634964A1 (en) 2020-04-15
US20200140445A1 (en) 2020-05-07
JP2020523309A (ja) 2020-08-06
BR112019025813A2 (pt) 2020-07-07
AU2018281131A1 (en) 2019-12-05
WO2018226771A1 (en) 2018-12-13
EP3634964B1 (en) 2022-02-23
US10934294B2 (en) 2021-03-02
US20180354955A1 (en) 2018-12-13
RU2019144010A (ru) 2021-07-13
TW201902898A (zh) 2019-01-16
CA3064938A1 (en) 2018-12-13
AU2018281131B2 (en) 2022-01-20
RU2019144010A3 (es) 2021-10-01
CN111051308A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
MX2019014597A (es) Inhibidores de pirazolopirimidina de pde9.
TN2014000070A1 (en) Pyrimidine pde10 inhibitors
MX2017011935A (es) Compuestos de triazolil pirimidinona como inhibidores de la enzima fosfodiesterasa 2 (pde2).
WO2012044562A3 (en) Pyrazolopyrimidine pde10 inhibitors
WO2012044561A3 (en) 2-alkoxy pyrimidine pde10 inhibitors
WO2012054366A3 (en) Substituted amino-triazolyl pde10 inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
MX2015008860A (es) Inhibidores de 3-(benzoimidazol-2-il)-indazol de la senda de señalizacion de wnt y usos terapeuticos de los mismos.
EA201190303A1 (ru) ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
PH12018502378A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2017005284A (es) Nuevos derivados de pirazolopirimidina de la cinasa inductora de nf-kb (nk).
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
SA520420768B1 (ar) مركبات بنزين سلفوناميد واستخدامها كعوامل علاجية
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
WO2014150114A8 (en) Substituted pyridizinone derivatives as pde10 inhibitors
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MXPA05012081A (es) Derivados de pirimidina sustituidos.
MX2023010824A (es) Profarmacos de compuestos de pde10.
AR112073A1 (es) Inhibidores de pirazolopirimidina de pde9